<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975324</url>
  </required_header>
  <id_info>
    <org_study_id>Dalfampridine 13-265</org_study_id>
    <nct_id>NCT01975324</nct_id>
  </id_info>
  <brief_title>A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)</brief_title>
  <acronym>Ampyra</acronym>
  <official_title>Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuro-Ophthalmologic Associates, PC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuro-Ophthalmologic Associates, PC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine whether dalfampridine (Ampyra) can improve visual function in patients who have
      had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine whether dalfampridine can improve visual function in
      patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual
      impairment.

      The objective of this double masked crossover study is to determine whether visual function
      can be improved in numerous parameters.  This includes high contrast visual acuity, low
      contrast visual acuity, visual field, visual quality of life (VFQ-39), electrophysiology,
      multi focal electro retinography (mERG), visual evoked potential (VEP), and structure,
      spectral domain optical coherence tomography (OCT).

      Based on the promising results of the use of dalfampridine in Multiple Sclerosis (MS) and in
      stroke, we hypothesize that the patients with chronic stable deficits after nonarteritic
      ischemic optic neuropathy (NAION) will have improved visual function with the administration
      of dalfampridine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improve visual function</measure>
    <time_frame>two weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Arteritic Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>dalfampridine (ampyra) or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalfampridine (ampyra) or placebo 10mgs twice a day (b.i.d.)for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalfampridine</intervention_name>
    <description>dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks</description>
    <arm_group_label>dalfampridine (ampyra) or placebo</arm_group_label>
    <other_name>Ampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo (sugar pill) twice a day for two weeks</description>
    <arm_group_label>dalfampridine (ampyra) or placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NAION 6 months prior to enrollment

          -  visual acuity of 20/40 or worse

        Exclusion Criteria:

        Current use of Dalfampridine (Ampyra)

          -  Pregnancy

          -  History of seizures

          -  Renal Failure

          -  Not able to perform testing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark L Moster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuro-Ophthalmologic Associates, PC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria C Massini, COT</last_name>
    <phone>215-825-4725</phone>
    <email>mmassini@willseye.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Santa Maria, COT</last_name>
    <phone>215-928-3130</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neuro-Ophthalmologic Associates, PC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria C Massini, COT</last_name>
      <phone>215-825-4725</phone>
      <email>mmassini@willseye.org</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Santa Maria, COT</last_name>
      <phone>215-928-3130</phone>
    </contact_backup>
    <investigator>
      <last_name>Mark L Moster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert C Sergott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K; Ischemic Optic Neuropathy Decompression Trial Research Group. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002 Sep;134(3):317-28.</citation>
    <PMID>12208242</PMID>
  </reference>
  <reference>
    <citation>The ischemic optic neuropathy decompression trial (IONDT): design and methods. Control Clin Trials. 1998 Jun;19(3):276-96.</citation>
    <PMID>9620811</PMID>
  </reference>
  <reference>
    <citation>Bever CT Jr. 10 questions about 4-aminopyridine and the treatment of multiple sclerosis. Neurologist. 2009 May;15(3):161-2. doi: 10.1097/NRL.0b013e3181679be5.</citation>
    <PMID>19430274</PMID>
  </reference>
  <reference>
    <citation>Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1990 Feb;27(2):186-92.</citation>
    <PMID>2317014</PMID>
  </reference>
  <reference>
    <citation>Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983 Aug-Sep;60(3):353-62.</citation>
    <PMID>6631441</PMID>
  </reference>
  <reference>
    <citation>Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1987 Jan;21(1):71-7.</citation>
    <PMID>2435223</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, van Dongen MM, Dammers JW, Polman CH. Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities. Eur Neurol. 1992;32(4):231-4.</citation>
    <PMID>1324180</PMID>
  </reference>
  <reference>
    <citation>Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 1994 Jun;44(6):1054-9.</citation>
    <PMID>8208399</PMID>
  </reference>
  <reference>
    <citation>Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991 Sep;41(9):1344-8.</citation>
    <PMID>1891078</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol. 1994 Nov;51(11):1136-9.</citation>
    <PMID>7980110</PMID>
  </reference>
  <reference>
    <citation>Strupp M, Brandt T. Pharmacological advances in the treatment of neuro-otological and eye movement disorders. Curr Opin Neurol. 2006 Feb;19(1):33-40. Review.</citation>
    <PMID>16415675</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8.</citation>
    <PMID>19249634</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502.</citation>
    <PMID>20976768</PMID>
  </reference>
  <reference>
    <citation>Ho PW, Reutens DC, Phan TG, Wright PM, Markus R, Indra I, Young D, Donnan GA. Is white matter involved in patients entered into typical trials of neuroprotection? Stroke. 2005 Dec;36(12):2742-4. Epub 2005 Nov 3.</citation>
    <PMID>16269640</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuro-Ophthalmologic Associates, PC</investigator_affiliation>
    <investigator_full_name>Mark L. Moster, M.d.</investigator_full_name>
    <investigator_title>Neuro-Ophthalmologist</investigator_title>
  </responsible_party>
  <keyword>Ampyra</keyword>
  <keyword>NAION</keyword>
  <keyword>Dalfampridine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
